The global injectable benzodiazepines market is anticipated to grow steadily, with a projected growth rate exceeding 2.7% in 2020. Key drivers of this growth include increasing adoption of generic injectable benzodiazepines, rising prevalence of mental disorders, and short-term demand spikes caused by the COVID-19 pandemic, which has elevated anxiety levels globally. Short-acting injectable benzodiazepines are gaining significant traction as a preferred treatment option for mental health crises.
Injectable benzodiazepines serve as the first line of treatment for mental disorders such as depression, bipolar disorder, schizophrenia, dementia, anxiety, and autism. As per the World Health Organization (WHO) and leading mental health organizations, approximately 25% of the global population experiences mental health issues at least once in their lifetime, underscoring the critical need for effective treatment options like benzodiazepines.
In the United States, data from the National Survey on Drug Use and Health (NSDUH) indicates that around 46.6 million adults suffered from mental disorders in 2017, representing an 18–20% prevalence rate. In Europe, mental disorders affected 35–40% of the population in 2017, with chronic depression alone costing the EU approximately USD 47 billion in productivity losses. Asia-Pacific, led by India, accounts for a significant share of global mental health disorders, with over 68% of the population reported to have psychiatric conditions, making the region a high-growth market for injectable benzodiazepines.
The Anxiety and Depression Association of America reports that 40 million adults in the U.S. are affected by anxiety disorders annually, a number expected to rise due to increased stress levels and insufficient mental health care. These trends are fueling the demand for fast-acting injectable benzodiazepines that provide immediate relief during acute mental health crises.
A Full Report Overview – https://www.futuremarketinsights.com/reports/injectable-benzodiazepine-market
Key Takeaways:
- The injectable benzodiazepines market is expected to grow at over 2.7%, driven by rising mental health challenges and adoption of generic drugs.
- The U.S. and Europe dominate the market, with Asia-Pacific emerging as the fastest-growing region due to high prevalence rates.
- Short-acting injectable benzodiazepines are gaining popularity for addressing acute mental health crises effectively.
- Mental health awareness campaigns and rising healthcare investments are expected to sustain market growth in the coming years.
Key Growth Drivers
- Increasing Adoption of Generic Injectable Benzodiazepines:
- The growing acceptance and availability of generic forms of injectable benzodiazepines are expected to significantly contribute to market growth.
- Short-Term Demand Surge Due to COVID-19:
- The COVID-19 pandemic has led to increased anxiety levels among the general population, resulting in a short-term spike in demand for injectable benzodiazepine drugs.
- Rising Incidences of Mental Disorders:
- The prevalence of mental health disorders, such as depression, anxiety, bipolar disorder, and schizophrenia, is driving the use of injectable benzodiazepines as a first-line treatment option.
- Popularity of Short-Acting Injectable Benzodiazepines:
- There is a growing trend towards the use of short-acting injectable benzodiazepines, which are preferred for their rapid onset of action in acute settings.
- Support from Health Organizations:
- Organizations like the WHO and European Brain Council highlight that approximately 25% of the global population experiences mental disorders at some point in their lives, further emphasizing the need for effective treatments.
Market Statistics
- According to the National Survey on Drug Use and Health (NSDUH), about 46.6 million adults in the U.S. suffered from mental disorders in 2017, indicating a significant market potential for injectable benzodiazepines.
- In Europe, around 35-40% of individuals are affected by mental disorders, which correlates with high demand for these medications.
- The Asia-Pacific region shows a particularly high incidence of psychiatric disorders, with more than 68% of people reported to have such conditions, suggesting it will witness the highest growth rate in the injectable benzodiazepine market.
Challenges
- Low Profitability Margins:
- Despite growth prospects, low profitability margins remain a challenge for market players, necessitating cost management strategies and innovation.
The key players in the injectable benzodiazepines market include:
Americas
- Pfizer Inc.
- Akorn Inc
- Dash Pharmaceuticals LLC
- AdvaCare Pharma
Europe
- Hikma Pharmaceuticals (West-Ward Pharmaceuticals)
- F. Hoffmann-La Roche Ltd
- Hameln pharma ltd
- Teva Pharmaceutical Industries Ltd. (Actavis Pharma, Inc.)
- Accord Healthcare Ltd
Asia Pacific
- Sun Pharmaceutical Industries Limited
- Taj Pharmaceuticals Limited
- Troy Laboratories Pty Ltd
- Intas Pharmaceuticals Limited
- Martin Dow
Key Segments of Injectable benzodiazepines Market
FMI’s study on the injectable benzodiazepines market offers information divided into three important segments – drug class, indication, time of action, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug Class
- Diazepam
- Lorazepam
- Midazolam
Time of Action
- Short Acting
- Long Acting
Indication
- Agitation & Aggression
- Anxiety
- Alcohol Withdrawal
- Muscle Spasm
- Seizures
- Tetanus
- Sedation
- Anaesthesia
- Insomnia
- Status Epilepticus
Distribution Channel
- Hospital
- Ambulatory Surgical centers
- Diagnostics Centers
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube